Literature DB >> 6175835

Combined use of prazosin and beta-blockers in hypertension.

G S Stokes, J Raftos, R G Lewis, A S Mitchell, D Jeremy, G W Frost, I R Thornell.   

Abstract

Combined use of prazosin and beta-blockers in a hypertension clinic over a 3-year period was surveyed by means of a computerized record system. Of the 1,250 patients in the clinic, 171 (14%) had been treated with this combination for periods averaging 17 months. Prazosin was administered with a beta 1-selective beta-blocker in 94 cases and with a beta 1 + beta 2-blocker in 100 cases; 23 patients had received treatment with both combinations. Diuretics were given in 86% of cases and other antihypertensive drugs in 19%. The population treated had a high incidence of severe hypertension, with initial diastolic pressure greater than 120 mm Hg in 38% and between 100 and 120 mm Hg in 50%. The percentage of patients with diastolic pressure less than 100 mm Hg was 12% initially and 79% at the end of the treatment period. Side effects necessitated withdrawal of therapy in 35 cases. These were referable in 19 cases to prazosin and in 16 to beta-blockers. Prazosin was found to be more effective in lowering blood pressure in combination with beta 1-blockers than with beta 1 + beta 2-blockers, although there were fewer severe side effects with beta 1-blockers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175835     DOI: 10.1097/00005344-198200041-00034

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects?

Authors:  A M MacConnachie; D Maclean
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 3.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.